Evaluation of antiplatelet effects of different dosages of aspirin in type 2 diabetic patients.

Karolinska Institute0 个研究点目标入组 30 人开始时间: 2007年7月6日最近更新: 2022年4月19日

适应症

试验速览

暂无简介。

•1) Type 2 DM with micro or macro-angiopathy.
•2) Patients with need for aspirin treatment or already on aspirin treatment.
•2) Age 50-75 years
•3) HbA1C 6-9 %
•3) Equal number of males and females
•4) Antecubital forearm veins allowing technically good sampling for platelet studies.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1) Diet controlled DM.
•2) Acute or chronic kidney disease
•3) Acute or chronic liver disease
•4) Need for treatment with anticoagulants, clopidogrel, NSAID’s, or thiazolidinediones.
•5) Thrombocytopenia (platelet count <150 x 109/L)
•6) Anticipated need for alteration of concomitant drug therapy during the course of the study.
•7) Enrolment in another clinical study.
•8) Contraindication(s) to aspirin treatment.
•9) A history of gastric or duodenal peptic ulcer disease.
•10) Acute ischemic stroke, acute coronary syndrome or revascularization procedure in the past 6 months.

发起方

Karolinska Institute